Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase 3 inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and i...
11080 Roselle Street
San Diego, CA 92121
Founded in 2000
Ambit Biosciences Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Aug 12 14
Ambit Biosciences Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of USD 26,000 against USD 11,547,000 a year ago. Loss from operations was USD 10,557,000 against income from operations of USD 2,686,000 a year ago. Net loss was USD 8,286,000 against net income of USD 5,160,000 a year ago. The decrease in revenue of USD 11.5 million was primarily due to the termination of the company's collaboration with Astellas Pharma, effective September 2013.
For the six months, the company reported revenues of USD 58,000 against USD 18,139,000 a year ago. Loss from operations was USD 20,090,000 against USD 1,503,000 a year ago. Net loss was USD 17,284,000 against USD 3,142,000 a year ago.
Ambit Biosciences Mulls Acquisitions
Aug 12 14
Ambit Biosciences Corporation (NasdaqGM:AMBI) has filed a shelf registration. Ambit Biosciences may use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.
Ambit Biosciences Corporation to Report Q2, 2014 Operating Results on Aug 12, 2014
Jul 29 14
Ambit Biosciences Corporation announced that they will report Q2, 2014 operating results at 5:00 PM, Eastern Standard Time on Aug 12, 2014